这是一篇来自已证抗体库的有关人类 activation induced cytidine deaminase的综述,是根据31篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合activation induced cytidine deaminase 抗体。
activation induced cytidine deaminase 同义词: AID; ARP2; CDA2; HEL-S-284; HIGM2

赛默飞世尔
小鼠 单克隆(ZA001)
  • 免疫组化-石蜡切片; 人类; 1:500; 图 1, 2
赛默飞世尔 activation induced cytidine deaminase抗体(生活科学, ZA001)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:500 (图 1, 2). Exp Eye Res (2020) ncbi
小鼠 单克隆(ZA001)
  • 免疫沉淀; 小鼠; 1:500; 图 1c
赛默飞世尔 activation induced cytidine deaminase抗体(生活技术, 392500)被用于被用于免疫沉淀在小鼠样本上浓度为1:500 (图 1c). Cell Res (2018) ncbi
小鼠 单克隆(ZA001)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 1d
赛默飞世尔 activation induced cytidine deaminase抗体(Invitrogen, ZA001)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (图 1d). Histopathology (2017) ncbi
大鼠 单克隆(mAID-2)
  • 免疫印迹; 小鼠; 图 1a
赛默飞世尔 activation induced cytidine deaminase抗体(eBioScience, 14-5959-82)被用于被用于免疫印迹在小鼠样本上 (图 1a). Nature (2017) ncbi
小鼠 单克隆(ZA001)
  • 免疫组化-石蜡切片; 人类; 1:100; 表 2
赛默飞世尔 activation induced cytidine deaminase抗体(Invitrogen, ZA001)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (表 2). Virchows Arch (2016) ncbi
大鼠 单克隆(mAID-2)
  • 免疫印迹; 人类; 图 2b
赛默飞世尔 activation induced cytidine deaminase抗体(eBioscience, mAID-2)被用于被用于免疫印迹在人类样本上 (图 2b). J Exp Med (2016) ncbi
大鼠 单克隆(mAID-2)
  • 流式细胞仪; 小鼠; 图 1c
赛默飞世尔 activation induced cytidine deaminase抗体(eBiosciences, mAID-2)被用于被用于流式细胞仪在小鼠样本上 (图 1c). J Exp Med (2016) ncbi
小鼠 单克隆(ZA001)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 1a
赛默飞世尔 activation induced cytidine deaminase抗体(Invitrogen, ZA001)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (图 1a). Hum Pathol (2016) ncbi
小鼠 单克隆(ZA001)
  • 免疫印迹; 鸡; 图 1
赛默飞世尔 activation induced cytidine deaminase抗体(Invitrogen, 39-2500)被用于被用于免疫印迹在鸡样本上 (图 1). PLoS ONE (2016) ncbi
小鼠 单克隆(ZA001)
  • 免疫组化; 人类; 图 4
赛默飞世尔 activation induced cytidine deaminase抗体(Invitrogen, ZA001)被用于被用于免疫组化在人类样本上 (图 4). Leuk Lymphoma (2016) ncbi
小鼠 单克隆(ZA001)
  • 免疫印迹; 小鼠; 图 10A
赛默飞世尔 activation induced cytidine deaminase抗体(Cell Signaling, 39-2500)被用于被用于免疫印迹在小鼠样本上 (图 10A). J Immunol (2015) ncbi
小鼠 单克隆(ZA001)
  • 免疫组化; 人类; 图 3
赛默飞世尔 activation induced cytidine deaminase抗体(生活技术, 39-2500)被用于被用于免疫组化在人类样本上 (图 3). Blood (2015) ncbi
小鼠 单克隆(ZA001)
  • 染色质免疫沉淀 ; 人类
赛默飞世尔 activation induced cytidine deaminase抗体(Invitrogen, ZA001)被用于被用于染色质免疫沉淀 在人类样本上. Leuk Lymphoma (2015) ncbi
小鼠 单克隆(ZA001)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 activation induced cytidine deaminase抗体(生活技术, ZA001)被用于被用于免疫组化-石蜡切片在人类样本上. Am J Transplant (2014) ncbi
小鼠 单克隆(ZA001)
  • 免疫组化-石蜡切片; 人类; 1:100
赛默飞世尔 activation induced cytidine deaminase抗体(Invitrogen, 39-250)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100. Anticancer Res (2014) ncbi
小鼠 单克隆(ZA001)
  • 免疫组化-石蜡切片; 人类
赛默飞世尔 activation induced cytidine deaminase抗体(Invitrogen, clone ZA001)被用于被用于免疫组化-石蜡切片在人类样本上. PLoS ONE (2014) ncbi
大鼠 单克隆(mAID-2)
  • 免疫印迹; 小鼠; 图 S2
赛默飞世尔 activation induced cytidine deaminase抗体(eBioscience, K4698)被用于被用于免疫印迹在小鼠样本上 (图 S2). Proc Natl Acad Sci U S A (2014) ncbi
小鼠 单克隆(ZA001)
  • 免疫组化; 人类; 1:100
赛默飞世尔 activation induced cytidine deaminase抗体(Invitrogen, 39-250)被用于被用于免疫组化在人类样本上浓度为1:100. Anticancer Res (2014) ncbi
小鼠 单克隆(ZA001)
  • 免疫细胞化学; 人类; 1:200
  • 免疫印迹; 人类; 1:1000
赛默飞世尔 activation induced cytidine deaminase抗体(Invitrogen, 39-2500)被用于被用于免疫细胞化学在人类样本上浓度为1:200 和 被用于免疫印迹在人类样本上浓度为1:1000. Exp Cell Res (2014) ncbi
小鼠 单克隆(ZA001)
  • 染色质免疫沉淀 ; 人类
  • 免疫细胞化学; 人类
  • 免疫印迹; 人类
赛默飞世尔 activation induced cytidine deaminase抗体(Invitrogen, 39-2500)被用于被用于染色质免疫沉淀 在人类样本上, 被用于免疫细胞化学在人类样本上 和 被用于免疫印迹在人类样本上. PLoS ONE (2013) ncbi
大鼠 单克隆(mAID-2)
  • 免疫组化-冰冻切片; 小鼠
赛默飞世尔 activation induced cytidine deaminase抗体(eBioscience, mAID-2)被用于被用于免疫组化-冰冻切片在小鼠样本上. Arthritis Rheum (2013) ncbi
小鼠 单克隆(ZA001)
  • 免疫组化-石蜡切片; 人类; 图 2
赛默飞世尔 activation induced cytidine deaminase抗体(Invitrogen, ZA001)被用于被用于免疫组化-石蜡切片在人类样本上 (图 2). PLoS ONE (2011) ncbi
小鼠 单克隆(ZA001)
  • 免疫印迹; 人类; 图 1
赛默飞世尔 activation induced cytidine deaminase抗体(Zymed, ZA001)被用于被用于免疫印迹在人类样本上 (图 1). Ann Surg Oncol (2011) ncbi
小鼠 单克隆(ZA001)
  • 免疫组化-石蜡切片; 人类; 1:40; 图 1
赛默飞世尔 activation induced cytidine deaminase抗体(Zymed Laboratories, clone ZA001)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:40 (图 1). Mod Pathol (2010) ncbi
小鼠 单克隆(ZA001)
  • 免疫印迹; 小鼠
赛默飞世尔 activation induced cytidine deaminase抗体(Zymed, 39-2500)被用于被用于免疫印迹在小鼠样本上. J Immunol (2010) ncbi
Active Motif
单克隆(328.8b)
  • 免疫印迹基因敲除验证; 人类; 图 2l
Active Motif activation induced cytidine deaminase抗体(Active Motif, 39886)被用于被用于免疫印迹基因敲除验证在人类样本上 (图 2l). Leukemia (2018) ncbi
赛信通(上海)生物试剂有限公司
domestic rabbit 单克隆(30F12)
  • 免疫印迹; 人类; 图 4a
  • 免疫印迹基因敲除验证; 小鼠; 图 3c, 3d
赛信通(上海)生物试剂有限公司 activation induced cytidine deaminase抗体(Cell Signaling, 4949)被用于被用于免疫印迹在人类样本上 (图 4a) 和 被用于免疫印迹基因敲除验证在小鼠样本上 (图 3c, 3d). Leukemia (2022) ncbi
小鼠 单克隆(L7E7)
  • 免疫印迹; 小鼠; 图 s1c
赛信通(上海)生物试剂有限公司 activation induced cytidine deaminase抗体(Cell Signaling, L7E7)被用于被用于免疫印迹在小鼠样本上 (图 s1c). Nat Commun (2018) ncbi
MBL International
小鼠 单克隆(1E4)
  • 免疫印迹; 人类; 1:2000; 图 s1f
MBL International activation induced cytidine deaminase抗体(MBL, M3-214-3)被用于被用于免疫印迹在人类样本上浓度为1:2000 (图 s1f). Nucleic Acids Res (2019) ncbi
小鼠 单克隆(1E4)
  • 免疫印迹; 人类; 图 1d
MBL International activation induced cytidine deaminase抗体(MBL, M214-3)被用于被用于免疫印迹在人类样本上 (图 1d). Cell Rep (2019) ncbi
小鼠 单克隆(1E4)
  • 免疫印迹; 人类; 图 2a
MBL International activation induced cytidine deaminase抗体(MBL, M214-3)被用于被用于免疫印迹在人类样本上 (图 2a). Genes Dev (2017) ncbi
文章列表
  1. Lee A, Pingali S, Pinilla Ibarz J, Atchison M, Koumenis C, Argon Y, et al. Loss of AID exacerbates the malignant progression of CLL. Leukemia. 2022;36:2430-2442 pubmed 出版商
  2. Epps S, Coplin N, Luthert P, Dick A, Coupland S, Nicholson L. Features of ectopic lymphoid-like structures in human uveitis. Exp Eye Res. 2020;191:107901 pubmed 出版商
  3. Hyle J, Zhang Y, Wright S, Xu B, Shao Y, Easton J, et al. Acute depletion of CTCF directly affects MYC regulation through loss of enhancer-promoter looping. Nucleic Acids Res. 2019;: pubmed 出版商
  4. Davidson L, Francis L, Cordiner R, Eaton J, Estell C, Macias S, et al. Rapid Depletion of DIS3, EXOSC10, or XRN2 Reveals the Immediate Impact of Exoribonucleolysis on Nuclear RNA Metabolism and Transcriptional Control. Cell Rep. 2019;26:2779-2791.e5 pubmed 出版商
  5. Chen J, Cai Z, Bai M, Yu X, Zhang C, Cao C, et al. The RNA-binding protein ROD1/PTBP3 cotranscriptionally defines AID-loading sites to mediate antibody class switch in mammalian genomes. Cell Res. 2018;28:981-995 pubmed 出版商
  6. Teater M, Domínguez P, Redmond D, Chen Z, Ennishi D, Scott D, et al. AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nat Commun. 2018;9:222 pubmed 出版商
  7. Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, et al. Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia. 2018;32:364-375 pubmed 出版商
  8. Verdanet E, Dereure O, René C, Tempier A, Benammar Hafidi A, Gallo M, et al. Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas. Histopathology. 2017;71:648-660 pubmed 出版商
  9. Natsume T, Nishimura K, Minocherhomji S, Bhowmick R, Hickson I, Kanemaki M. Acute inactivation of the replicative helicase in human cells triggers MCM8-9-dependent DNA synthesis. Genes Dev. 2017;31:816-829 pubmed 出版商
  10. Compagno M, Wang Q, Pighi C, Cheong T, Meng F, Poggio T, et al. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. Nature. 2017;542:489-493 pubmed 出版商
  11. Gallo M, Cacheux V, Vincent L, Bret C, Tempier A, Guittard C, et al. Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14. Virchows Arch. 2016;469:697-706 pubmed
  12. Kalchschmidt J, Bashford Rogers R, Paschos K, Gillman A, Styles C, Kellam P, et al. Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells. J Exp Med. 2016;213:921-8 pubmed 出版商
  13. Jackson S, Jacobs H, Arkatkar T, Dam E, Scharping N, Kolhatkar N, et al. B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J Exp Med. 2016;213:733-50 pubmed 出版商
  14. Shi Y, Zhao X, Durkin L, Rogers H, Hsi E. Aberrant activation-induced cytidine deaminase expression in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. Hum Pathol. 2016;52:173-8 pubmed 出版商
  15. Williams A, Maman Y, Alinikula J, Schatz D. Bcl6 Is Required for Somatic Hypermutation and Gene Conversion in Chicken DT40 Cells. PLoS ONE. 2016;11:e0149146 pubmed 出版商
  16. Scherer F, Navarrete M, Bertinetti Lapatki C, Boehm J, Schmitt Graeff A, Veelken H. Isotype-switched follicular lymphoma displays dissociation between activation-induced cytidine deaminase expression and somatic hypermutation. Leuk Lymphoma. 2016;57:151-60 pubmed 出版商
  17. Pone E, Lam T, Lou Z, Wang R, Chen Y, Liu D, et al. B cell Rab7 mediates induction of activation-induced cytidine deaminase expression and class-switching in T-dependent and T-independent antibody responses. J Immunol. 2015;194:3065-78 pubmed 出版商
  18. Correia C, Schneider P, Dai H, Dogan A, Maurer M, Church A, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 2015;125:658-67 pubmed 出版商
  19. Wright R, Slemmons K, Vaughan A. Estradiol induces gene proximity and MLL-MLLT3 fusion in an activation-induced cytidine deaminase-mediated pathway. Leuk Lymphoma. 2015;56:1460-5 pubmed 出版商
  20. Meier D, Docena G, Ramisch D, Toscanini U, Berardi G, Gondolesi G, et al. Immunological status of isolated lymphoid follicles after intestinal transplantation. Am J Transplant. 2014;14:2148-58 pubmed 出版商
  21. Batsaikhan B, Yoshikawa K, Kurita N, Iwata T, Takasu C, Kashihara H, et al. Expression of Stathmin1 in gastric adenocarcinoma. Anticancer Res. 2014;34:4217-21 pubmed
  22. Meshcheryakova A, Tamandl D, Bajna E, Stift J, Mittlboeck M, Svoboda M, et al. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS ONE. 2014;9:e99008 pubmed 出版商
  23. Yousif A, Stanlie A, Mondal S, Honjo T, Begum N. Differential regulation of S-region hypermutation and class-switch recombination by noncanonical functions of uracil DNA glycosylase. Proc Natl Acad Sci U S A. 2014;111:E1016-24 pubmed 出版商
  24. Batsaikhan B, Kurita N, Iwata T, Sato H, Yoshikawa K, Takasu C, et al. The role of activation-induced cytidine deaminase expression in gastric adenocarcinoma. Anticancer Res. 2014;34:995-1000 pubmed
  25. Hu Y, Ericsson I, Doseth B, Liabakk N, Krokan H, Kavli B. Activation-induced cytidine deaminase (AID) is localized to subnuclear domains enriched in splicing factors. Exp Cell Res. 2014;322:178-92 pubmed 出版商
  26. Lam T, Thomas L, White C, Li G, Pone E, Xu Z, et al. Scaffold functions of 14-3-3 adaptors in B cell immunoglobulin class switch DNA recombination. PLoS ONE. 2013;8:e80414 pubmed 出版商
  27. Wang J, New J, Xie S, Yang P, Wu Q, Li J, et al. Extension of the germinal center stage of B cell development promotes autoantibodies in BXD2 mice. Arthritis Rheum. 2013;65:2703-12 pubmed 出版商
  28. Mechtcheriakova D, Sobanov Y, Holtappels G, Bajna E, Svoboda M, Jaritz M, et al. Activation-induced cytidine deaminase (AID)-associated multigene signature to assess impact of AID in etiology of diseases with inflammatory component. PLoS ONE. 2011;6:e25611 pubmed 出版商
  29. Shinmura K, Igarashi H, Goto M, Tao H, Yamada H, Matsuura S, et al. Aberrant expression and mutation-inducing activity of AID in human lung cancer. Ann Surg Oncol. 2011;18:2084-92 pubmed 出版商
  30. Liu T, Chen S, Kuo S, Cheng A, Lin C. E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: possible correlation with stage and treatment response. Mod Pathol. 2010;23:1507-17 pubmed 出版商
  31. Misaghi S, Garris C, Sun Y, Nguyen A, Zhang J, Sebrell A, et al. Increased targeting of donor switch region and IgE in Sgamma1-deficient B cells. J Immunol. 2010;185:166-73 pubmed 出版商